Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 3Phase 1 2Phase EARLY_PHASE1 1Phase 3 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 182Neoplasms 115Prostatic Neoplasms 103Multiple Myeloma 86Glioblastoma 82Pancreatic Neoplasms 76Glioma 66Brain Neoplasms 60Lung Neoplasms 58Head and Neck Neoplasms 57Melanoma 55Colorectal Neoplasms 55Carcinoma, Non-Small-Cell Lung 53Leukemia, Myeloid, Acute 51Carcinoma, Hepatocellular 51Recurrence 47Squamous Cell Carcinoma of Head and Neck 46Ovarian Neoplasms 45Lymphoma 40Lymphoma, Non-Hodgkin 37Sarcoma 36Lymphoma, B-Cell 36Stomach Neoplasms 34Precursor Cell Lymphoblastic Leukemia-Lymphoma 34Neoplasm Metastasis 34Solid Tumor 31Hematologic Neoplasms 31Carcinoma, Renal Cell 30Polycystic Ovary Syndrome 27Burkitt Lymphoma 27

Interventions

tislelizumab 1teprotumumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Insulin-Like Growth Factor I, Resistance To × Clear all
NCT06866548 2025-12-04

Safety and Efficacy Evaluation of Anti IGF-1R Monoclonal Antibody Combined With Anti-PD-1 Monoclonal Antibody in Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer

Shanghai Changzheng Hospital

Phase EARLY_PHASE1 Active not recruiting
7 enrolled
Genitourinary

Insulin-Like Growth Factor I, Resistance To, Neoplasm Metastasis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡